- Trial phase
- Phase 1/1b
- Time to market
- Likely 5+ years, if successful. Currently in Phase 1/1b with proof-of-concept data expected end of 2026. Netherton syndrome is an ultra-rare disease, which could support an accelerated development path, but the program is still very early.
- Why 3/10
- No hard binary catalyst like a PDUFA or pivotal readout is scheduled. The next datapoint is proof-of-concept data from the Phase 1 Part 4 study (up to 12 patients) expected by year-end 2026. BCX17725 is a very early-stage (Phase 1) pipeline asset for an ultra-rare disease at a company with a ~$2.5B market cap and a $600M+ revenue commercial product (ORLADEYO), making it a minor value driver for the stock.
BCX17725 is too early-stage to move the needle for BCRX on its own. The stock's primary catalysts are ORLADEYO revenue growth and navenibart Phase 3 data (Q3 2027). Watch for BCX17725 proof-of-concept data by year-end 2026 as a potential pipeline-validation signal, but do not size a position around it.
Price Chart
Executive Summary
BCX17725 is an investigational KLK5 inhibitor in Phase 1/1b development for Netherton syndrome, an ultra-rare genetic skin disorder with no approved targeted therapies. It is BioCryst's first protein therapeutic to reach the clinic. Dosing is ongoing in Part 4 of the Phase 1 trial (up to 12 patients for 12 weeks), with proof-of-concept data expected by year-end 2026. For BCRX, which generated ~$601M in ORLADEYO revenue in 2025 (a commercial-stage HAE drug) and now has a pipeline anchored by the Phase 3 asset navenibart (HAE, data Q3 2027), BCX17725 is a small, early-stage pipeline component and a minor value driver for the stock.
How It Works
BCX17725 is a protein therapeutic designed to treat Netherton syndrome by inhibiting kallikrein 5 (KLK5), an enzyme in the skin that is overactive in people with the disease. By blocking this enzyme, the drug aims to correct the underlying protein deficiency that causes the severe skin symptoms of Netherton syndrome. It is BioCryst's first protein therapeutic to reach clinical trials.
Trial Status
First-in-human, 4-part Phase 1/1b study (NCT06539507) is enrolling. Parts 1 and 2 (healthy volunteers, single and multiple ascending doses) have been completed. Part 3 (1-3 Netherton syndrome patients, 4 weeks of treatment) is ongoing. Part 4 (up to 12 patients, 12 weeks of treatment) began dosing around May 2026. Proof-of-concept data from Part 4 is expected by the end of 2026.
The Two-Sided Case
Upcoming Catalysts
- Proof-of-concept data from Phase 1 Part 4 study (up to 12 Netherton syndrome patients) expected by year-end 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOCRYST PHARMACEUTICALS INC 8-K BCRX ·Originating report